# Atalanta Therapeutics

> Atalanta Therapeutics is a Boston-based biotechnology company pioneering RNA interference (RNAi) therapies for diseases of the brain and spinal cord. Its proprietary divalent small interfering RNA (di-siRNA) platform is engineered to silence disease-causing genes durably and broadly across the central nervous system - long the hardest place in the body to reach with RNAi. Founded out of the RNA Therapeutics Institute at UMass Chan Medical School by leaders in the RNAi field, including Nobel laureate Craig Mello, the company is advancing wholly-owned programs in KCNT1-related epilepsy and Huntington's disease toward the clinic, alongside collaborations with Biogen and Genentech.

- **Founded:** 2018
- **Headquarters:** Boston, Massachusetts, United States
- **Founders:** Anastasia Khvorova (Scientific Co-Founder (RNA Therapeutics Institute, UMass Chan)), Craig Mello (Scientific Co-Founder (Nobel laureate, RNAi co-discoverer)), Neil Aronin (Scientific Co-Founder (UMass Chan Medical School))
- **Team size:** ~46 employees
- **Products:** di-siRNA platform, KCNT1-related epilepsy program, Huntington's disease program, Partnered CNS pipeline
- **Notable:** Launched in January 2021 with $110M in committed funding and partnerships with Biogen and Genentech., Closed an oversubscribed $97M Series B in January 2025 co-led by EQT Life Sciences and Sanofi Ventures., Founded by leaders of the RNAi field, including Nobel laureate Craig Mello.

## Products & services

- **di-siRNA platform** — A proprietary divalent small interfering RNA architecture - two siRNA strands joined into a branched molecule - engineered for broad, durable distribution and selective gene silencing across the brain and spinal cord.
- **KCNT1-related epilepsy program** — A wholly-owned investigational RNAi therapy targeting the genetic driver of KCNT1-related epilepsy, with preclinical data published in 2025 and an IND submission planned.
- **Huntington's disease program** — A wholly-owned investigational di-siRNA therapy aimed at silencing the huntingtin gene across the CNS, advancing toward clinical trials.
- **Partnered CNS pipeline** — Collaborations applying the di-siRNA platform to additional neurological targets with Biogen and Genentech (Roche Group).

## Achievements

- Launched in January 2021 with $110M in committed funding and partnerships with Biogen and Genentech.
- Closed an oversubscribed $97M Series B in January 2025 co-led by EQT Life Sciences and Sanofi Ventures.
- Founded by leaders of the RNAi field, including Nobel laureate Craig Mello.
- Published preclinical data for its KCNT1-related epilepsy RNAi therapy in 2025.
- Advancing two wholly-owned RNAi programs toward IND submissions and clinical trials.

## Latest updates

- **2025-06** — Announced leadership transitions: Joanne Kotz named CEO and Douglas Pagan appointed CFO & COO.
- **2025-04** — Published preclinical data for its investigational RNAi therapy for KCNT1-related epilepsy.
- **2025-01** — Closed an oversubscribed $97M Series B to advance two RNAi therapies for CNS diseases to clinical trials.
- **2024-05** — Expanded executive team with appointments of a Chief Medical Officer and Chief Financial Officer.

## Links

- Website: https://atalantatx.com
- LinkedIn: https://www.linkedin.com/company/atalanta-therapeutics
- Twitter/X: https://twitter.com/AtalantaTx

---

Profile page: https://yespress.io/atalanta-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-06-16